2023
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership
Snyder R, Burtness B, Cho M, Del Rivero J, Doroshow D, Hitchcock K, Kalyan A, Kim C, Lukovic J, Parikh A, Sanford N, Singh B, Shen C, Shroff R, Vijayvergia N, Goodman K, Kunz P. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership. Journal Of The National Cancer Institute 2023, 115: 1132-1138. PMID: 37364007, PMCID: PMC11009492, DOI: 10.1093/jnci/djad121.Peer-Reviewed Original ResearchConceptsNational Clinical Trials NetworkTrial leadershipClinical Trials NetworkDesign of trialsNational Cancer InstituteTask ForceCancer careClinical trialsNovel therapiesGastrointestinal oncologyCancer InstituteTrials NetworkMultidisciplinary investigatorsTrialsCooperative groupsBroader populationCancer researchOncology
2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Journal Of The National Cancer Institute 2022, 114: 1619-1627. PMID: 36053203, PMCID: PMC9745425, DOI: 10.1093/jnci/djac163.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaSquamous cell carcinomaClinical trialsCell carcinomaTrial designTP53 mutationsNational Clinical Trials NetworkMetastatic disease settingsClinical trial developmentClinical Trials NetworkNovel therapeutic approachesNational Cancer InstituteMetastatic headTP53-mutated tumorsWorse outcomesClinical studiesFrequent genetic eventTherapeutic approachesCancer InstituteTrial developmentBreakout groupsPatientsDisease settingsBiomarker integrationTrials Network
2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le Q, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2016, 123: 1259-1271. PMID: 27906454, PMCID: PMC5705038, DOI: 10.1002/cncr.30449.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteClinical trialsCancer InstituteRecurrent/metastatic HNSCCNational Clinical Trials NetworkNeck squamous cell carcinomaClinical trial conceptsRandomized phase 2Use of immunotherapySquamous cell carcinomaStandard of careDifferent patient populationsClinical Trials NetworkClinical trial designNew immunotherapeutic targetsPhase 2Key immune componentsDifferent immunotherapiesOncologic communityImmunotherapeutic trialsMetastatic HNSCCOropharyngeal cancerImmunotherapeutic targetCell carcinomaPatient population
2012
Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head & Neck 2012, 35: 160-164. PMID: 22302641, PMCID: PMC4037756, DOI: 10.1002/hed.22929.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionCarcinoma, Squamous CellDatabases, FactualFemaleFunctional LateralityHead and Neck NeoplasmsHumansIncidenceLymph NodesMaleNeoplasm InvasivenessNeoplasm StagingPapillomavirus InfectionsRetrospective StudiesRisk AssessmentSEER ProgramSex DistributionSurvival AnalysisTonsillar NeoplasmsUnited StatesConceptsBilateral neck diseaseHuman papillomavirus eraPrimary tonsillar cancerTonsillar cancerNeck diseaseAdvanced neck diseaseEnd Results ProgramNational Cancer InstituteCancer incidence dataIpsilateral diseaseAnnual incidenceResults ProgramRegional spread patternsBiologic behaviorCancer InstituteCancerDiseaseIncidence dataIncidenceSpread patternTherapyEpidemiology